James J. Ignatz-Hoover

1.1k total citations · 1 hit paper
25 papers, 749 citations indexed

About

James J. Ignatz-Hoover is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, James J. Ignatz-Hoover has authored 25 papers receiving a total of 749 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 15 papers in Hematology and 13 papers in Oncology. Recurrent topics in James J. Ignatz-Hoover's work include Multiple Myeloma Research and Treatments (9 papers), Peptidase Inhibition and Analysis (9 papers) and Acute Myeloid Leukemia Research (6 papers). James J. Ignatz-Hoover is often cited by papers focused on Multiple Myeloma Research and Treatments (9 papers), Peptidase Inhibition and Analysis (9 papers) and Acute Myeloid Leukemia Research (6 papers). James J. Ignatz-Hoover collaborates with scholars based in United States, South Korea and China. James J. Ignatz-Hoover's co-authors include James J. Driscoll, Ehsan Malek, Byung‐Gyu Kim, Sung Hee Choi, David N. Wald, Muthulekha Swamydas, Stephen Moreton, Kalpana Gupta, Jeffry Katz and Pingfu Fu and has published in prestigious journals such as Nature Communications, Blood and Cancer Research.

In The Last Decade

James J. Ignatz-Hoover

22 papers receiving 744 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Novel therapies emerging in oncology to target the TGF-β pathway

2021 288 citations Byung‐Gyu Kim, Ehsan Malek et al. Journal of Hematology & Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James J. Ignatz-Hoover United States	12	379	273	251	124	81	25	749
Alessandra Metelli United States	11	380 1.0×	373 1.4×	304 1.2×	84 0.7×	84 1.0×	11	893
Shweta Dubey India	10	352 0.9×	152 0.6×	247 1.0×	66 0.5×	164 2.0×	23	719
Hind Medyouf Germany	13	526 1.4×	298 1.1×	220 0.9×	247 2.0×	157 1.9×	23	976
Fang Dong China	15	340 0.9×	168 0.6×	259 1.0×	215 1.7×	187 2.3×	62	778
Emma F. Barry Australia	14	360 0.9×	346 1.3×	396 1.6×	274 2.2×	47 0.6×	18	942
Justine E. Roderick United States	14	715 1.9×	256 0.9×	452 1.8×	244 2.0×	121 1.5×	22	1.2k
Hayrettin Guvén Sweden	13	195 0.5×	329 1.2×	358 1.4×	90 0.7×	62 0.8×	17	654
Lenka Kubiczková Czechia	11	479 1.3×	217 0.8×	107 0.4×	193 1.6×	159 2.0×	17	782
Djoke van Gosliga Netherlands	13	570 1.5×	155 0.6×	119 0.5×	237 1.9×	65 0.8×	18	978

Countries citing papers authored by James J. Ignatz-Hoover

Since Specialization

Citations

This map shows the geographic impact of James J. Ignatz-Hoover's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James J. Ignatz-Hoover with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James J. Ignatz-Hoover more than expected).

Fields of papers citing papers by James J. Ignatz-Hoover

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James J. Ignatz-Hoover. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James J. Ignatz-Hoover. The network helps show where James J. Ignatz-Hoover may publish in the future.

Co-authorship network of co-authors of James J. Ignatz-Hoover

This figure shows the co-authorship network connecting the top 25 collaborators of James J. Ignatz-Hoover. A scholar is included among the top collaborators of James J. Ignatz-Hoover based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James J. Ignatz-Hoover. James J. Ignatz-Hoover is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ignatz-Hoover, James J., et al.. (2025). Real-World Evidence for Autologous Stem Cell Transplantation in Elderly Multiple Myeloma Patients. Transplantation and Cellular Therapy. 31(2). S437–S438.

Malek, Ehsan, Priyanka S. Rana, Muthulekha Swamydas, et al.. (2024). The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial. Nature Communications. 15(1). 7388–7388. 12 indexed citations

Rana, Priyanka S., James J. Ignatz-Hoover, Byung‐Gyu Kim, et al.. (2024). HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity. Cancer Research Communications. 4(6). 1517–1532. 5 indexed citations

Rana, Priyanka S., James J. Ignatz-Hoover, Amber L. Mosley, et al.. (2024). Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity. Molecular Cancer Therapeutics. 23(12). 1743–1760. 9 indexed citations

Ignatz-Hoover, James J., et al.. (2024). Real-World Evidence for Autologous Stem Cell Transplantation in Elderly Multiple Myeloma Patients. Blood. 144(Supplement 1). 3773–3773.

Driscoll, James J., Priyanka S. Rana, Ehsan Malek, & James J. Ignatz-Hoover. (2023). An Immunoproteasome Activator That Increases MHC Class I Antigen Presentation to Enhance Anti-Tumor Immunity. Blood. 142(Supplement 1). 3642–3642. 1 indexed citations

Ignatz-Hoover, James J., et al.. (2023). Current and Emerging Strategies to Treat Urothelial Carcinoma. Cancers. 15(19). 4886–4886. 10 indexed citations

Rana, Priyanka S., James J. Ignatz-Hoover, & James J. Driscoll. (2023). Targeting Proteasomes and the MHC Class I Antigen Presentation Machinery to Treat Cancer, Infections and Age-Related Diseases. Cancers. 15(23). 5632–5632. 13 indexed citations

Rana, Priyanka S., James J. Ignatz-Hoover, & James J. Driscoll. (2023). Abstract 6235: Discovery of novel HDAC6 inhibitors that enhance proteasomal activity to boost antigen presentation and trigger anti-myeloma T-cell immunity. Cancer Research. 83(7_Supplement). 6235–6235. 2 indexed citations

10.

Ignatz-Hoover, James J., et al.. (2022). Proteasome Regulatory Atpases PSMC2 and PSMC6 Modulate Proteosome Inhibitor Sensitivity and Correlate with Survival in Multiple Myeloma. Blood. 140(Supplement 1). 4305–4306. 1 indexed citations

11.

Ignatz-Hoover, James J. & James J. Driscoll. (2022). Therapeutics to harness the immune microenvironment in multiple myeloma. Cancer Drug Resistance. 5(3). 647–61. 13 indexed citations

12.

Swamydas, Muthulekha, et al.. (2022). Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma. Journal of Hematology & Oncology. 15(1). 75 indexed citations

13.

Ignatz-Hoover, James J., et al.. (2022). Targeting Proteasomes in Cancer and Infectious Disease: A Parallel Strategy to Treat Malignancies and Microbes. Frontiers in Cellular and Infection Microbiology. 12. 925804–925804. 11 indexed citations

14.

Kim, Byung‐Gyu, Ehsan Malek, Sung Hee Choi, James J. Ignatz-Hoover, & James J. Driscoll. (2021). Novel therapies emerging in oncology to target the TGF-β pathway. Journal of Hematology & Oncology. 14(1). 55–55. 288 indexed citations breakdown →

15.

Ueda, Masumi, Tammy Stefan, Lindsay Stetson, et al.. (2020). Phase I Trial of Lithium and Tretinoin for Treatment of Relapsed and Refractory Non-promyelocytic Acute Myeloid Leukemia. Frontiers in Oncology. 10. 327–327. 9 indexed citations

16.

Ignatz-Hoover, James J., Victoria Wang, Masumi Ueda, et al.. (2018). Aberrant GSK3β nuclear localization promotes AML growth and drug resistance. Blood Advances. 2(21). 2890–2903. 25 indexed citations

17.

Gupta, Kalpana, Tammy Stefan, James J. Ignatz-Hoover, et al.. (2016). GSK-3 Inhibition Sensitizes Acute Myeloid Leukemia Cells to 1,25D-Mediated Differentiation. Cancer Research. 76(9). 2743–2753. 35 indexed citations

18.

Hu, Sophia, Masumi Ueda, Lindsay Stetson, et al.. (2016). A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity. Molecular Cancer Therapeutics. 15(7). 1485–1494. 35 indexed citations

19.

Ignatz-Hoover, James J., Stephen Moreton, Amitabha Chakrabarti, et al.. (2014). The role of TLR8 signaling in acute myeloid leukemia differentiation. Leukemia. 29(4). 918–926. 59 indexed citations

20.

Ignatz-Hoover, James J., et al.. (2009). Interleukin-12 Is the Optimum Cytokine To Expand Human Th17 Cells In Vitro. Clinical and Vaccine Immunology. 16(6). 798–805. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact